Loading...
XNYS
PBH
Market cap2.27bUSD
Oct 08, Last price  
47.87USD
1D
0.63%
1Q
-2.11%
Jan 2017
-8.12%
IPO
167.13%
Name

Prestige Consumer Healthcare Inc

Chart & performance

D1W1MN
XNYS:PBH chart
P/E
11.92
P/S
2.08
EPS
4.02
Div yield, %
—
Shrs. gr., 5y
-0.76%
Rev. gr., 5y
2.91%
Revenues
1.09b
-4.31%
318,634,000326,603,000312,715,000302,023,000336,510,000441,085,000623,597,000601,881,000714,623,000806,247,000882,060,0001,041,179,000975,777,000963,010,000943,365,0001,086,812,0001,127,725,0001,125,357,0001,137,762,0001,088,705,000
Net income
190m
-11.32%
36,078,00033,919,000-186,776,00032,115,00029,220,00037,212,00065,505,00072,615,00078,260,00099,907,00069,395,000339,570,000-35,800,000142,281,000164,682,000205,381,000-82,306,000209,339,000214,605,000190,301,000
CFO
258m
+2.43%
71,899,00044,989,00066,679,00059,427,00086,670,00067,452,000137,605,000111,582,000156,255,000174,350,000147,772,000210,110,000189,284,000217,124,000235,607,000259,922,000229,716,000248,926,000251,515,000257,627,000
Dividend
Sep 27, 20180.475 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

Key people

Chairman of the Board, President, Chief Executive Officer · since 2017
Christine Sacco
Chief Financial Officer · since 2016
Timothy J. Connors
Executive Vice President - Sales and Marketing · since 2011
Jeffrey Zerillo
Senior Vice President, Operations · since 2018
William C. PPool
Senior Vice President, General Counsel and Corporate Secretary · since 2016
Director · since 2020
John E. Byom
Independent Director · since 2006
Gary E. Costley
Lead Independent Director · since 2009
Independent Director
Independent Director · since 2015
Independent Director · since 2016
IPO date
Feb 10, 2005
Employees
560
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT